SITC Cancer Immunotherapy Guidelines are a collection of clinical practice guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus...
Despite regulatory approval of several immune-based treatments for cancer in the past decade, a number of barriers remain to be addressed in order to fully harness the therapeutic potential of the immune system and provide benefits for patients with cancer. As part of the Cancer Moonshot...
FOR IMMEDIATE RELEASE Aug. 3, 2020 MILWAUKEE – The Society for Immunotherapy of Cancer (SITC), the world’s leading member-driven organization dedicated solely to cancer immunotherapy, has published a clinical practice guideline specific to the use of immunotherapy for multiple myeloma, a type...
SITC Congratulates 2020 Election Winners The Society for Immunotherapy of Cancer (SITC) is pleased to share the results of the 2020 SITC Election. The candidates who received the most votes during the election, which took place May 6-20, 2020, are: Newly Elected SITC Vice President ...
The rapid rise to fame of immuno-oncology (IO) drugs has generated unprecedented interest in the industry, patients and doctors, and has had a major impact in the treatment of most cancers. An interesting aspect in the clinical development of many IO agents is the increasing reliance on...
As the field of cancer immunotherapy continues to advance at a fast pace, treatment approaches and drug development are evolving rapidly to maximize patient benefit. New agents are commonly evaluated for activity in patients who had previously received a programmed death receptor 1 (PD-1)...
Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase of interrogated genomic sequence, demonstrates predictive biomarker potential for the identification of patients with cancer most likely to respond to immune checkpoint inhibitors. TMB is optimally calculated...
header image SITC Cancer Immunotherapy Guidelines Expert Panels are comprised of leaders in the immuno-oncology field who provide interdisciplinary perspectives including medical oncology, community oncology, radiation oncology, surgery, pathology, and nursing as well as other specializations,...
header image The coronavirus (COVID-19) pandemic has affected all aspects of healthcare and the oncology and immuno-oncology communities may face unique challenges in regards to patient care. As immuno-oncology practitioners treat patients during the pandemic, it has also become apparent that...
Response criteria developed when cytotoxic chemotherapy was the predominant therapeutic modality to treat patients with cancer, do not capture the full spectrum of tumor response patterns observed with anti-PD-1/PD-L1 antibody treatment. iRECIST was developed to capture both typical and atypical...
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us